BIO
254.45
+7.97 (+3.23%)
Bio-Rad Laboratories, Inc. Class A · NYSE
- Sector Health Technology
- Industry Medical Specialties
- Website bio-rad.com
- Employees(FY) 8000
- ISIN US0905722072
Performance
-1.36%
1W
-16.94%
1M
-24.33%
3M
-22.0%
6M
-22.54%
YTD
-23.45%
1Y
Profile
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Technical Analysis of BIO 2025-03-14
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2025-02-15 10:05
- 2025-02-15 08:03
- 2025-02-14 17:14
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover(Morningstar Research)
- 2025-02-14 12:07
Analyst Report: Bio-Rad Laboratories, Inc.(Morningstar Research)
- 2025-02-13 16:20
- 2025-02-13 16:15
- 2025-02-13 03:20
- 2025-02-13 03:15
- 2025-02-11 08:46
OncoCyte prices $29.1M equity offering(TipRanks)
- 2025-02-10 08:30
Oncocyte Prices $29.1 Million Equity Offering(GlobeNewswire)
- 2025-02-04 19:00
BIO: Lowering target price to $279.00(Argus Research)
- 2025-01-28 19:00
BIO: Raising target price to $294.00(Argus Research)
- 2025-01-27 17:00
- 2025-01-21 19:00
BIO: Lowering target price to $283.00(Argus Research)
- 2025-01-14 19:00
BIO: Raising target price to $294.00(Argus Research)
- 2025-01-08 08:15
- 2025-01-07 19:15
- 2025-01-07 19:00
BIO: Rating decreased to a SELL(Argus Research)
- 2025-01-02 16:30
- 2025-01-02 03:30
- 2024-12-30 19:00
BIO: Lowering target price to $343.00(Argus Research)
- 2024-12-26 08:47
- 2024-12-23 19:00
BIO: Rating increased to a HOLD(Argus Research)
- 2024-12-17 19:00
BIO: Lowering target price to $277.00(Argus Research)
- 2024-12-10 19:00
BIO: Lowering target price to $278.00(Argus Research)
- 2024-12-03 19:00
BIO: Raising target price to $291.00(Argus Research)
- 2024-11-29 07:43
- 2024-11-26 19:00
BIO: Raising target price to $277.00(Argus Research)
- 2024-11-24 07:05
Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory(Insidermonkey)
- 2024-11-21 09:00
Page 1 of 5
previousnext
Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.